ECE2019 Guided Posters Calcium and Bone 2 (11 abstracts)
FGF-23 beyond the kidney: a new bone mass regulator in the general population
Stefana Catalina Bilha 1 , Maria-Christina Ungureanu 1 , Alina Andreea Gatu 1 , Anca Matei 1 , Alexandru Florescu 1 , Adrian Aancute 2 , Valentin Zaharia 2 , Cristina Preda 1 , Adrian Covic 1 & Dumitru Branisteanu 1
1‘Grigore T. Popa’ University of Medicine and Pharmacy Iasi, Iasi, Romania; 2‘St. Spiridon’ Emergency Hospital, Iasi, Romania.
Aim: Fibroblast growth factor-23 (FGF-23) has been proposed as a predictor of bone abnormalities in chronic kidney disease patients (CKD), with recent data showing that it may also predict bone mass in the general population. We aimed at investigating the relationship between FGF-23 and bone mass parameters in apparently healthy individuals, according to sex, menopausal and nutritional status.
Materials and methods: Bone mass (bone mineral density-BMD, bone mineral content-BMC; assessed by Dual X-Ray Absorptiometry-DXA), body composition (DXA evaluation), and also the serum levels of FGF-23, parathormone (PTH), 25(OH)D3, bone resorption marker C-terminal telopeptide of type I collagen (CTx) and leptin were determined from 123 apparently healthy volunteers (38 premenopausal women, 55 postmenopausal women and 30 young and middle-aged men). Primary osteoporosis under treatment and secondary osteoporosis (including CKD) were excluded.
Results: FGF-23 was negatively and independently associated with BMD and/or BMC in all groups, explaining up to 10% (P<0.05) of femoral neck BMD variance in postmenopausal women, and up to 20% (P<0.01) and 32% (P=0.001) of 1/3 radius BMC variance in premenopausal women and men, respectively. FGF-23 was increased in postmenopausal women with osteopenia/osteoporosis, but was not an accurate discriminator of normal versus low bone mass (AUC=0.622±0.076) according to ROC analysis. FGF-23 did not correlate with vitamin D, CTx, body weight, body composition parameters or leptin. FGF-23 was independently associated with PTH in premenopausal women and men only.
Conclusions: FGF-23 was negatively associated with bone mass parameters in both sexes, but was not a discriminator of high accuracy between normal bone mass and osteopenia/osteoporosis in postmenopausal women. The mechanism through which FGF-23 acts upon bone seems not to be mediated by leptin and, thus, requires further investigation. FGF-23 may find its place as a new marker for fine tuning the evaluation of primary osteoporosis and its associated fracture risk.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more